Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.

G. Giaccone; E.F. Smit; M. de Jonge; E Dansin; E Briasoulis; A. Ardizzoni; JY Douillard; D Spaeth; D Lacombe; B Baron; P Bachmann; P Fumoleau

doi:10.1016/j.ejca.2003.10.027

Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.

G. Giaccone, E.F. Smit, M. de Jonge, E Dansin, E Briasoulis, A. Ardizzoni, JY Douillard, D Spaeth, D Lacombe, B Baron, P Bachmann, P Fumoleau

VU University medical center

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	667-72
Journal	European Journal of Cancer
Volume	40
Issue number	5
DOIs	https://doi.org/10.1016/j.ejca.2003.10.027
Publication status	Published - 2004

Access to Document

10.1016/j.ejca.2003.10.027

Embargoed Document

170737
Final published version, 170 KB

Cite this

Giaccone, G., Smit, E. F., de Jonge, M., Dansin, E., Briasoulis, E., Ardizzoni, A., Douillard, JY., Spaeth, D., Lacombe, D., Baron, B., Bachmann, P., & Fumoleau, P. (2004). Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. European Journal of Cancer, 40(5), 667-72. https://doi.org/10.1016/j.ejca.2003.10.027

Giaccone, G. ; Smit, E.F. ; de Jonge, M. ; Dansin, E ; Briasoulis, E ; Ardizzoni, A. ; Douillard, JY ; Spaeth, D ; Lacombe, D ; Baron, B ; Bachmann, P ; Fumoleau, P. / Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. In: European Journal of Cancer. 2004 ; Vol. 40, No. 5. pp. 667-72.

@article{aec863e7572341b4918b2241fd6bef7f,

title = "Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.",

author = "G. Giaccone and E.F. Smit and {de Jonge}, M. and E Dansin and E Briasoulis and A. Ardizzoni and JY Douillard and D Spaeth and D Lacombe and B Baron and P Bachmann and P Fumoleau",

year = "2004",

doi = "10.1016/j.ejca.2003.10.027",

language = "English",

volume = "40",

pages = "667--72",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Pergamon",

number = "5",

}

Giaccone, G, Smit, EF, de Jonge, M, Dansin, E, Briasoulis, E, Ardizzoni, A, Douillard, JY, Spaeth, D, Lacombe, D, Baron, B, Bachmann, P & Fumoleau, P 2004, 'Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.', European Journal of Cancer, vol. 40, no. 5, pp. 667-72. https://doi.org/10.1016/j.ejca.2003.10.027

Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. / Giaccone, G.; Smit, E.F.; de Jonge, M.; Dansin, E; Briasoulis, E; Ardizzoni, A.; Douillard, JY; Spaeth, D; Lacombe, D; Baron, B; Bachmann, P; Fumoleau, P.

In: European Journal of Cancer, Vol. 40, No. 5, 2004, p. 667-72.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.

AU - Giaccone, G.

AU - Smit, E.F.

AU - de Jonge, M.

AU - Dansin, E

AU - Briasoulis, E

AU - Ardizzoni, A.

AU - Douillard, JY

AU - Spaeth, D

AU - Lacombe, D

AU - Baron, B

AU - Bachmann, P

AU - Fumoleau, P

PY - 2004

Y1 - 2004

U2 - 10.1016/j.ejca.2003.10.027

DO - 10.1016/j.ejca.2003.10.027

M3 - Article

VL - 40

SP - 667

EP - 672

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -